keyword
MENU ▼
Read by QxMD icon Read
search

Rim Kim NSABP

keyword
https://www.readbyqxmd.com/read/27812689/association-of-polymorphisms-in-fcgr2a-and-fcgr3a-with-degree-of-trastuzumab-benefit-in-the-adjuvant-treatment-of-erbb2-her2-positive-breast-cancer-analysis-of-the-nsabp-b-31-trial
#1
Patrick G Gavin, Nan Song, S Rim Kim, Corey Lipchik, Nicole L Johnson, Hanna Bandos, Melanie Finnigan, Priya Rastogi, Louis Fehrenbacher, Eleftherios P Mamounas, Sandra M Swain, D Lawrence Wickerham, Charles E Geyer, Jong-Hyeon Jeong, Joseph P Costantino, Norman Wolmark, Soonmyung Paik, Kay L Pogue-Geile
Importance: Preclinical models and studies in the metastatic and neoadjuvant settings suggest that single nucleotide polymorphisms in FCGR3A and FCGR2A may be associated with differential response to trastuzumab in the treatment of ERBB2/HER2-positive breast cancer, by modulating antibody-dependent cell-mediated cytotoxic effects. Objective: To evaluate the effect of FCGR2A and FCGR3A polymorphisms on trastuzumab efficacy in the adjuvant treatment of ERBB2/HER2-positive breast cancer...
November 3, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27270348/clinical-outcome-from-oxaliplatin-treatment-in-stage-ii-iii-colon-cancer-according-to-intrinsic-subtypes-secondary-analysis-of-nsabp-c-07-nrg-oncology-randomized-clinical-trial
#2
Nan Song, Katherine L Pogue-Geile, Patrick G Gavin, Greg Yothers, S Rim Kim, Nicole L Johnson, Corey Lipchik, Carmen J Allegra, Nicholas J Petrelli, Michael J O'Connell, Norman Wolmark, Soonmyung Paik
IMPORTANCE: Oxaliplatin added to fluorouracil plus leucovorin therapy for patients with colon cancer has been shown to provide significant but modest absolute benefit for disease-free survival. However, acute and chronic neurotoxic effects from this regimen underscore the need for markers that predict oxaliplatin benefit. OBJECTIVE: To test our hypothesis that molecular subtypes of colon cancer would be associated with differential prognosis and benefit from oxaliplatin added to fluorouracil plus leucovorin therapy...
September 1, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/25559813/intrinsic-subtypes-pik3ca-mutation-and-the-degree-of-benefit-from-adjuvant-trastuzumab-in-the-nsabp-b-31-trial
#3
Katherine L Pogue-Geile, Nan Song, Jong-Hyeon Jeong, Patrick G Gavin, Seong-Rim Kim, Nicole L Blackmon, Melanie Finnigan, Priya Rastogi, Louis Fehrenbacher, Eleftherios P Mamounas, Sandra M Swain, D Lawrence Wickerham, Charles E Geyer, Joseph P Costantino, Norman Wolmark, Soonmyung Paik
PURPOSE: Considerable molecular heterogeneity exists among human epidermal growth factor receptor 2 (HER2) -positive breast cancer regarding gene expression and mutation profiling. Evidence from preclinical, clinical neoadjuvant, and metastatic clinical trials suggested that PIK3CA mutational status and PAM50 intrinsic subtype of a tumor were markers of response to anti-HER2 therapies. We evaluated the predictive value of these two biomarkers in the adjuvant setting using archived tumor blocks from National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31...
April 20, 2015: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/24262440/predicting-degree-of-benefit-from-adjuvant-trastuzumab-in-nsabp-trial-b-31
#4
RANDOMIZED CONTROLLED TRIAL
Katherine L Pogue-Geile, Chungyeul Kim, Jong-Hyeon Jeong, Noriko Tanaka, Hanna Bandos, Patrick G Gavin, Debora Fumagalli, Lynn C Goldstein, Nour Sneige, Eike Burandt, Yusuke Taniyama, Olga L Bohn, Ahwon Lee, Seung-Il Kim, Megan L Reilly, Matthew Y Remillard, Nicole L Blackmon, Seong-Rim Kim, Zachary D Horne, Priya Rastogi, Louis Fehrenbacher, Edward H Romond, Sandra M Swain, Eleftherios P Mamounas, D Lawrence Wickerham, Charles E Geyer, Joseph P Costantino, Norman Wolmark, Soonmyung Paik
BACKGROUND: National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31 suggested the efficacy of adjuvant trastuzumab, even in HER2-negative breast cancer. This finding prompted us to develop a predictive model for degree of benefit from trastuzumab using archived tumor blocks from B-31. METHODS: Case subjects with tumor blocks were randomly divided into discovery (n = 588) and confirmation cohorts (n = 991). A predictive model was built from the discovery cohort through gene expression profiling of 462 genes with nCounter assay...
December 4, 2013: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/23821759/defective-mismatch-repair-and-benefit-from-bevacizumab-for-colon-cancer-findings-from-nsabp-c-08
#5
RANDOMIZED CONTROLLED TRIAL
Kay Pogue-Geile, Greg Yothers, Yusuke Taniyama, Noriko Tanaka, Patrick Gavin, Linda Colangelo, Nicole Blackmon, Corey Lipchik, Seong Rim Kim, Saima Sharif, Carmen Allegra, Nicholas Petrelli, Michael J O'Connell, Norman Wolmark, Soonmyung Paik
National Surgical Adjuvant Breast and Bowel Project protocol C-08 tested the worth of adding 1 year of bevacizumab to oxaliplatin-based standard adjuvant chemotherapy regimen in the treatment of stage II/III colon cancer. Although the overall result was negative, the possibility that a molecularly defined subset could benefit from bevacizumab cannot be ruled out. We performed post hoc Cox regression analyses to test for marker-by-treatment interactions for standard pathological features and survival analyses using the Kaplan-Meier method...
July 3, 2013: Journal of the National Cancer Institute
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"